Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Sanjoy K, Datta"'
Autor:
Selvamuthu Poongulali, Sylviane Poncelet, Silvana Maria Quintana, Sanjoy K Datta, Kiat Ruxrungtham, Lan Lin, Beatriz Grinsztejn, Khuanchai Supparatpinyo, Monique Dodet, Florence Thomas-Jooris, Nagalingeswaran Kumarasamy, Frank Struyf, Julio Cesar Teixeira, Naveen Karkada, Fernanda Tavares-da-Silva, Vinay Kulkarni, Smita Joshi, Nicolas Folschweiller, Dorothee Meric Camilleri, Bruno Salaun, Ploenchan Chetchotisakd, Dominique Descamps, Gary Dubin, Tawee Chotpitayasunondh, Luciano Zubaran Goldani, Cecilia Roteli-Martins, Damien Friel, Marjan Hezareh, Partha Basu
Publikováno v:
EClinicalMedicine
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Background Women living with HIV (WLWH) are at higher risk of acquisition and progression of human papillomavirus (HPV) infection. Evidence on effect of HPV vaccination in this population is limited. Methods This phase IV randomized controlled observ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b6d19612db6b5233527478783cf83c
https://doi.org/10.1016/j.eclinm.2020.100353
https://doi.org/10.1016/j.eclinm.2020.100353
Autor:
Sanjoy K Datta, Marie-Pierre David, Geoff Garnett, Kari Natunen, David G. Jenkins, Dan Bi, Dan Apter, Eero Pukkala, Jorma Paavonen, Tiina Eriksson, Simopekka Vänskä, Gary Dubin, Matti Lehtinen, Iacopo Baussano, Frank Struyf
Publikováno v:
Vaccine. 33:1284-1290
High-risk human papillomaviruses (hrHPV) cause anogenital and oropharyngeal cancers. HPV-16/18 virus-like particle vaccine formulated with an AS04 adjuvant is very efficacious against hrHPV associated precancers but the herd effects of different vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478c895bd74b176a8e6659463b12228b
https://doi.org/10.1016/j.vaccine.2014.12.019
https://doi.org/10.1016/j.vaccine.2014.12.019
Autor:
Jia-Xi Yu, Cheng-Fu Zhang, Dan Bi, Juan Li, Marie-Pierre David, Frank Struyf, Ying Hong, Sanjoy K Datta, Wen Chen, Yi-Ju Zhang, Feng-Cai Zhu, Qin-Jing Pan, Xiaoping Yang, Yuemei Hu, Yan-Shu Zhang, Xun Zhang, Helen Zhang, Haiwen Tang, Marie Lebacq, Fang-Hui Zhao, Dominique Descamps
Publikováno v:
International Journal of Cancer. 135:2612-2622
This phase II/III, double-blind, randomized trial assessed the efficacy, immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in young Chinese women (ClinicalTrials.gov registration {"type":"clinical-trial","attrs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae5f1caada82fa2de1763f11f723c77f
https://doi.org/10.1002/ijc.28897
https://doi.org/10.1002/ijc.28897
Autor:
Juan Li, Jian Guo Yang, Yuemei Hu, Dominique Descamps, Junzhi Wang, Sanjoy K Datta, Dan Bi, Qinyong Dai, Guodong Xia, Xiaoping Yang, Xiang Zhang, Frank Struyf, P.V. Suryakiran, Feng-Cai Zhu, Hui Zhao, Haiwen Tang
Publikováno v:
Human Vaccines & Immunotherapeutics. 10:1795-1806
Immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine were evaluated in healthy Chinese females aged 9-45 years in 2 phase IIIB, randomized, controlled trials. Girls aged 9-17 years (ClinicalTrials.gov, NCT00996125
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c60dd543952efa1f83d90ca99d2d9352
https://doi.org/10.4161/hv.28702
https://doi.org/10.4161/hv.28702
Autor:
Tiina Eriksson, Dan Bi, Eero Pukkala, Frank Struyf, Kari Natunen, Julia Zima, Mari Hokkanen, Jorma Paavonen, Marie-Pierre David, Matti Lehtinen, Dan Apter, Maria-Genalin Angelo, Gary Dubin, Sanjoy K Datta
Publikováno v:
Human Vaccines & Immunotherapeutics
This community-randomized controlled trial was initiated to assess the overall and herd effects of 2 different human papillomavirus (HPV) immunization strategies in over 80,000 girls and boys aged 1215 y in 33 communities in Finland (ClinicalTrials.g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21ab80cb794deeb6b0d97f8ced0051a
https://pubmed.ncbi.nlm.nih.gov/27841725
https://pubmed.ncbi.nlm.nih.gov/27841725
Autor:
Htay Htay Han, Sanjoy K Datta, Hans L. Bock, Andrée Delem, Sujit K. Bhattacharya, Dutta P, Gagandeep Kang, Anand Pandit, P.V. Suryakiran, Anil Narang, Anuradha Bose
Publikováno v:
Human Vaccines. 5:414-419
This study was undertaken to assess the immunogenicity, reactogenicity and safety of two doses of an oral live-attenuated human rotavirus vaccine, strain RIX4414 (Rotarix()) in an Indian setting.The seroconversion rate observed one month post-dose 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18042bc90dbc27ca193a51c0971e1af9
https://doi.org/10.4161/hv.5.6.8176
https://doi.org/10.4161/hv.5.6.8176
Autor:
Kusuma Gopala, Sanjoy K Datta, Himali Ihalagama, Saman Rohitha, Jing Chen, Anco Molijn, Kanishka Karunaratne, Johannes E. Schmidt, Shailesh Mehta
Publikováno v:
BMC Cancer
Background Cervical cancer ranks second among all cancers reported in Sri Lankan women. This study assessed the prevalence and type-distribution of human papillomavirus (HPV) among Sri Lankan women with invasive cervical cancer (ICC) and pre-cancerou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021f05381b5855ce29e779e406e567ba
https://doi.org/10.1186/1471-2407-14-116
https://doi.org/10.1186/1471-2407-14-116
Autor:
Fang-Hui, Zhao, Feng-Cai, Zhu, Wen, Chen, Juan, Li, Yue-Mei, Hu, Ying, Hong, Yi-Ju, Zhang, Qin-Jing, Pan, Jia-Hong, Zhu, Xun, Zhang, Yong, Chen, Haiwen, Tang, Helen, Zhang, Christelle, Durand, Sanjoy K, Datta, Frank, Struyf, Dan, Bi
Publikováno v:
International Journal of Cancer. Journal International du Cancer
Baseline human papillomavirus (HPV) prevalence and type distribution were evaluated in young Chinese women enrolled in a clinical trial of an HPV vaccine (ClinicalTrials.gov registration NCT00779766). Cervical specimens and blood samples were collect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1dbac3707656c7990af498eeb3780f4a
https://pubmed.ncbi.nlm.nih.gov/24740547
https://pubmed.ncbi.nlm.nih.gov/24740547
Autor:
Mark H, Einstein, Mira, Baron, Myron J, Levin, Archana, Chatterjee, Bradley, Fox, Sofia, Scholar, Jeffrey, Rosen, Nahida, Chakhtoura, Marie, Lebacq, Robbert, van der Most, Philippe, Moris, Sandra L, Giannini, Anne, Schuind, Sanjoy K, Datta, Dominique, Descamps, Michael W, Warren
Publikováno v:
Human vaccines. 7(12)
Protection against oncogenic non-vaccine types (cross-protection) offered by human papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical efficacy data suggest the two licensed vaccines [HPV-16/18 vaccine, GlaxoSm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a7ab67d25f9dd06c0deea8f9bae66c
https://pubmed.ncbi.nlm.nih.gov/22048172
https://pubmed.ncbi.nlm.nih.gov/22048172
Autor:
Mark H, Einstein, Mira, Baron, Myron J, Levin, Archana, Chatterjee, Bradley, Fox, Sofia, Scholar, Jeffrey, Rosen, Nahida, Chakhtoura, Dorothée, Meric, Francis J, Dessy, Sanjoy K, Datta, Dominique, Descamps, Gary, Dubin, Michael W, Warren
Publikováno v:
Human vaccines. 7(12)
In this observer-blind study (NCT00423046), women (N = 1,106), stratified by age (18–26, 27–35, 36–45 y), were randomized (1:1) to receive the HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6) or the HPV-6/11/16/18 vac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8092d36fe214678c7981e7a0ac27d411
https://pubmed.ncbi.nlm.nih.gov/22048173
https://pubmed.ncbi.nlm.nih.gov/22048173